Marginal ulcer

An ulcer that develops in the jejunal mucosa close to the anastomosis site following a gastroenterostomy procedure.


Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

A malignant non-seminomatous germ cell tumor arising from the testis.  It is characterized by a mixture of embryonal carcinoma and yolk sac morphologic elements.  Patients may present with painless or painful testicular swelling.


Osteoporotic Fractures

A pathologic bone fracture due to osteoporosis. It is generally caused by a fall from a standing height or lower and usually involves the spine, hip, or wrist.


Papulopustular Rash

biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

Skin eruption consisting of papules and pustules, most often appearing in the face, scalp, and upper trunk.  It is usually caused by corticosteroids or epidermal growth factor receptor inhibitors.


Low Grade Salivary Gland Carcinoma

A salivary gland carcinoma with low-grade histopathologic features.  It includes the salivary gland polymorphous low grade adenocarcinoma, salivary gland low grade cribriform cystadenocarcinoma, and low grade salivary gland mucoepidermoid carcinoma.  It usually follows a non-aggressive clinical course.


Low Grade Salivary Gland Mucoepidermoid Carcinoma

A salivary gland mucoepidermoid carcinoma with low-grade histopathologic features. It usually follows a non-aggressive clinical course.


High Grade Salivary Gland Carcinoma

A usually aggressive salivary gland carcinoma with high-grade histopathologic features.  It includes the salivary duct carcinoma, salivary gland oncocytic carcinoma, and high grade salivary gland mucoepidermoid carcinoma.


High Grade Salivary Gland Mucoepidermoid Carcinoma

A salivary gland mucoepidermoid carcinoma with high-grade histopathologic features. It usually follows an aggressive clinical course.


Adenocarcinoma of salivary gland

An adenocarcinoma arising from the salivary gland.  It includes the salivary gland polymorphous low grade adenocarcinoma, salivary gland oncocytic carcinoma, salivary gland mucinous adenocarcinoma, salivary gland low grade cribriform cystadenocarcinoma, salivary gland cystadenocarcinoma, salivary gland basal cell adenocarcinoma, salivary gland acinic cell carcinoma, salivary duct carcinoma, and salivary gland adenocarcinoma not otherwise specified.


BRAF V600E Mutation Present

A molecular finding indicating the presence of a BRAF V600E mutation in a tissue sample.


Diffuse large B-cell lymphoma associated with chronic inflammation

A diffuse large B-cell lymphoma arising in body cavities or narrow spaces of long standing chronic inflammation.  The classic example is the pyothorax-associated lymphoma that arises in the pleural cavity of patients with a history of long standing pyothorax.


Progressive Hairy Cell Leukemia Initial Treatment

A hairy cell leukemia requiring initial treatment because of the presence of signs of progression.  Signs of progression include cytopenia (especially if symptomatic), increasing splenomegaly, and infectious complications.  Therapy is not necessary if the patients are asymptomatic and the blood counts are maintained in an acceptable range.


High Grade B-Cell Lymphoma, Not Otherwise Specified

High-grade B-cell lymphoma with blastoid features or features between diffuse large B-cell lymphoma and Burkitt lymphoma that lacks MYC, BCL2, and BCL6 gene rearrangements.


Monoclonal B-Cell Lymphocytosis

A monoclonal expansion of B-lymphocytes with or without the characteristic immunophenotype of chronic lymphocytic leukemia. It precedes virtually all cases of chronic lymphocytic leukemia/small lymphocytic lymphoma.


One or More Positive Axillary Nodes

Presence of one or more lymph nodes in the area of the armpit in which cancerous cells have been detected.


B-lymphoblastic leukemia/lymphoma MLL rearranged

A B-lymphoblastic leukemia/lymphoma that is characterized by the presence of lymphoblasts that carry a translocation between the KMT2A gene at 11q23.3 and another gene partner resulting in the production of a KMT2A related fusion protein.


Hypodiploid B Acute Lymphoblastic Leukemia

A B-cell acute leukemia characterized by the presence of lymphoblasts which contain less than 46 chromosomes. It occurs in both children and adults. It has an unfavorable clinical outcome.


Recurrent Lip and Oral Cavity Carcinoma

The reemergence of lip and/or oral cavity carcinoma after a period of remission.


Follicular T-cell lymphoma

Follicular helper T-cell lymphoma with a predominantly follicular growth pattern.


Non-ST Elevation Myocardial Infarction by ECG Finding

An electrocardiographic finding of a myocardial infarction that does not produce elevations in the ST segment of the EKG.


Stage 1 chronic kidney disease

A type of chronic kidney disease with normal or increased glomerular filtration rate (GFR at least 90 mL/min/1.73 m2).


Stage 2 chronic kidney disease

A type of chronic kidney disease with mildly reduced glomerular filtration rate (GFR 60-89 mL/min/1.73 m2).


Stage 3 chronic kidney disease

A type of chronic kidney disease with moderately reduced glomerular filtration rate (GFR 30-59 mL/min/1.73 m2).


Stage 4 chronic kidney disease

A type of chronic kidney disease with severely reduced glomerular filtration rate (GFR 15-29 mL/min/1.73 m2).


Stage II Laryngeal Cancer AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: (Supraglottis) Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx.  (Glottis) Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility.  (Subglottis) Tumor extends to vocal cord(s) with normal or impaired mobility. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


left main coronary artery stenosis

Percent luminal narrowing of the left main coronary artery, at the point of maximal stenosis of the left main coronary artery.


Stage III Laryngeal Cancer AJCC v6 and v7

Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Supraglottis: Tumor limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility.  Subglottis: Tumor limited to the subglottis.  T2: Supraglottis: Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx.  Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility.  Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. T3: Supraglottis: Tumor limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, pre-epiglottic tissues, paraglottic space, and/or inner cortex of thyroid cartilage.  Glottis: Tumor limited to the larynx with vocal cord fixation and/or invasion of paraglottic space, and/or inner cortex of the thyroid cartilage.  Subglottis: Tumor limited to larynx with vocal cord fixation.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3cm or less in greatest dimension.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Regional Adrenal Gland Pheochromocytoma

A pheochromocytoma that has not spread to other regions.


Recurrent Adrenal Gland Pheochromocytoma

The reemergence of pheochromocytoma following surgical removal.


Stage III Oropharyngeal Carcinoma AJCC v6

Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N2, M0).  T3: Tumor more than 4 cm in greatest dimension.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6cm in greatest dimension.  M0: No distant metastasis. (AJCC 6th ed.)


Oropharyngeal cancer recurrent

The reemergence of oropharyngeal carcinoma after a period of remission.


Fractured vertebra

A partial or complete breakage of the vertebra.


Stage II Childhood Hodgkin Lymphoma

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Stage I Childhood Hodgkin Lymphoma

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE) (rare in Hodgkin lymphoma).


Stage III Childhood Hodgkin Lymphoma

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


Stage IV Childhood Hodgkin Lymphoma

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Recurrent Childhood Hodgkin Lymphoma

The reemergence of Hodgkin lymphoma after a period of remission during childhood.


Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma

A nodular lymphocyte predominant B-cell lymphoma occurring in children.


Childhood Lymphocyte-Depleted Classic Hodgkin Lymphoma

Lymphocyte-depleted classic Hodgkin lymphoma occurring in childhood.


Childhood Nodular Sclerosis Classic Hodgkin Lymphoma

Nodular sclerosis classic Hodgkin lymphoma occurring in childhood.


Childhood Mixed Cellularity Classic Hodgkin Lymphoma

Mixed cellularity classic Hodgkin lymphoma occurring in childhood.


Transitional cell cancer of renal pelvis and ureter metastatic

A urothelial carcinoma of the renal pelvis and ureter that has spread from its original site of growth to another anatomic site.


Metastatic Childhood Soft Tissue Sarcoma

A sarcoma that arises from the soft tissues during childhood and has spread from the original site of growth to another anatomic site.


Recurrent Childhood Soft Tissue Sarcoma

The reemergence of soft tissue sarcoma in childhood after a period of remission.


Chemotherapy-Related Leukemia

A leukemia arising as a result of the mutagenic effect of chemotherapy agents that are used for the treatment of a malignant tumor.


B-cell small lymphocytic lymphoma stage I

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


Ann Arbor Stage I Grade 1 Follicular Lymphoma


Ann Arbor Stage I Grade 2 Follicular Lymphoma


Ann Arbor Stage I Grade 3 Follicular Lymphoma


Stage I Adult Diffuse Small Cleaved Cell Lymphoma

Stage I: Involvement of a single lymph node region (I) or localized involvement of a single extralymphatic organ or site (IE). (from PDQ)


Stage I Adult Diffuse Mixed Cell Lymphoma


Stage I Adult Diffuse Large Cell Lymphoma


Stage I Ovarian Germ Cell Tumor AJCC v6 and v7

Stage I includes: (T1, N0, M0). T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Stage II Ovarian Germ Cell Tumor AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage III Ovarian Germ Cell Tumor AJCC v6 and v7

Stage III includes: T3, N0, M0. T3: Tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IV Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Recurrent Ovarian Germ Cell Tumor

The reemergence of ovarian germ cell tumor after a period of remission.


Childhood Synovial Sarcoma

A synovial sarcoma occurring in childhood.


Childhood Leiomyosarcoma

An aggressive malignant smooth muscle neoplasm, occurring in children.  It is characterized by a proliferation of neoplastic spindle cells.


Recurrent Adult Non-Hodgkin Lymphoma

The reemergence of non-Hodgkin lymphoma in adults after a period of remission.


Squamous Cell Carcinoma of Unknown Primary

A squamous cell carcinoma which has metastasized to another anatomic site and the original site of growth has not been identified.


Stage II Adult Non-Hodgkin Lymphoma

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). The number of regions involved may be indicated by a subscript (e.g., II3).


Stage III Adult Non-Hodgkin Lymphoma

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


Stage IV Adult Non-Hodgkin Lymphoma

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


B-cell small lymphocytic lymphoma stage II

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Ann Arbor Stage II Grade 1 Follicular Lymphoma


Ann Arbor Stage II Grade 2 Follicular Lymphoma


Stage II Adult Lymphoblastic Lymphoma

Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ)


B-cell small lymphocytic lymphoma stage III


Ann Arbor Stage III Grade 1 Follicular Lymphoma


Ann Arbor Stage III Grade 2 Follicular Lymphoma


Ann Arbor Stage III Grade 3 Follicular Lymphoma


Stage III Adult Diffuse Small Cleaved Cell Lymphoma

Stage III: Involvement of lymph node regions on both sides of the diaphragm (III) that may also be accompanied by localized involvement of an extralymphatic organ or site (IIIE), by involvement of the spleen (IIIS), or both (IIIS+E). (from PDQ)


Stage III Adult Diffuse Mixed Cell Lymphoma


Stage III Adult Diffuse Large Cell Lymphoma


B-cell small lymphocytic lymphoma stage IV


Ann Arbor Stage IV Grade 1 Follicular Lymphoma


Ann Arbor Stage IV Grade 2 Follicular Lymphoma


Ann Arbor Stage IV Grade 3 Follicular Lymphoma


Stage IV Adult Diffuse Small Cleaved Cell Lymphoma

Stage IV: Disseminated (multifocal) involvement of one or more extralymphatic sites with or without associated lymph node involvement or isolated extralymphatic organ involvement with distant (nonregional) nodal involvement. (PDQ)


Stage IV Adult Diffuse Mixed Cell Lymphoma


Stage IV Adult Diffuse Large Cell Lymphoma


B-cell small lymphocytic lymphoma recurrent

The reemergence of small lymphocytic lymphoma after a period of remission.


Recurrent Grade 1 Follicular Lymphoma

The reemergence of grade 1 follicular lymphoma after a period of remission.


Recurrent Grade 2 Follicular Lymphoma

The reemergence of grade 2 follicular lymphoma after a period of remission.


Recurrent Grade 3 Follicular Lymphoma

The reemergence of grade 3 follicular lymphoma after a period of remission.


Recurrent Adult Burkitt Lymphoma

The reemergence of adult Burkitt lymphoma after a period of remission.


Recurrent Adult Diffuse Mixed Cell Lymphoma

The reemergence of adult diffuse mixed cell lymphoma after a period of remission.


Recurrent Adult Diffuse Large Cell Lymphoma

The reemergence of adult diffuse large cell lymphoma after a period of remission.


Recurrent Adult Immunoblastic Lymphoma

The reemergence of adult immunoblastic lymphoma after a period of remission.


Recurrent Adult Lymphoblastic Lymphoma

The reemergence of adult lymphoblastic lymphoma after a period of remission.


Transitional cell cancer of the renal pelvis and ureter localized

Urothelial carcinoma of the renal pelvis or ureter that has not spread to adjacent tissues, regional lymph nodes, or distant anatomic sites.


Regional Urothelial Carcinoma of the Renal Pelvis and Ureter

Urothelial carcinoma of the renal pelvis or ureter that has spread to adjacent tissues and/or regional lymph nodes but not to distant anatomic sites.


Anterior Tongue Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the anterior two-thirds of the tongue.  It usually presents as a painful ulcerated or nodular lesion.


Posterior Tongue Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the base of the tongue.  It usually presents as a painful ulcerated lesion.


Verrucous carcinoma of the oral cavity stage I


Mucoepidermoid carcinoma of the oral cavity stage I

Stage I includes: T1, N0, M0.  T1: Tumor 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Adenoid cystic carcinoma of the oral cavity stage I


Verrucous carcinoma of the oral cavity stage II


Mucoepidermoid carcinoma of the oral cavity stage II

Stage II includes: T2, N0, M0. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Adenoid cystic carcinoma of the oral cavity stage II


Verrucous carcinoma of the oral cavity stage III


Mucoepidermoid carcinoma of the oral cavity stage III

Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor more than 4 cm in greatest dimension. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Adenoid cystic carcinoma of the oral cavity stage III


Verrucous carcinoma of the oral cavity stage IV


Stage IV Oral Cavity Mucoepidermoid Carcinoma AJCC v6 and v7

Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0);. IVB (Any T, N3, M0); (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a: (oral cavity) Tumor invades adjacent structures (e.g., through cortical bone, into deep [extrinsic] muscles of tongue, maxillary sinus, skin of face).  T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N2a: Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in dimension.  N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension.  N2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M1: Distant metastasis. (AJCC 6th and 7th eds.)


Adenoid cystic carcinoma of the oral cavity stage IV


Recurrent Lip Basal Cell Carcinoma

Reemergence of basal cell carcinoma of the lip after a period of remission.


Verrucous carcinoma of the oral cavity recurrent

Reemergence of verrucous carcinoma of the oral cavity after a period of remission.


Mucoepidermoid carcinoma of the oral cavity recurrent

The reemergence of mucoepidermoid carcinoma in the oral cavity after a period of remission.


Adenoid cystic carcinoma of the oral cavity recurrent

The reemergence of adenoid cystic carcinoma in the oral cavity after a period of remission.


Oropharyngeal squamous cell carcinoma stage I

Stage I includes: T1, N0, M0.  T1: Tumor 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Oropharyngeal squamous cell carcinoma stage II

Stage II includes: T2, N0, M0.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Oropharyngeal squamous cell carcinoma stage III

Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  T3: Tumor measuring more than 4 centimeters in greatest dimension or extension to lingual surface of epiglottis.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7

Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (T4b, Any N, M0); (Any T, N3, M0); IVC (Any T, Any N, M1). T4a: Tumor with moderately advanced local disease.  Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible.  Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of larynx. T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  T3: Tumor measuring more than 4 centimeters in greatest dimension or extension to lingual surface of epiglottis.  T4b: Tumor with very advanced local disease.  Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Tumor with metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


Oropharyngeal squamous cell carcinoma recurrent

Reemergence of squamous cell carcinoma of the oropharynx after a period of remission.


mixed phenotype acute leukemia, B/myeloid

An acute biphenotypic leukemia that is characterized by blasts which express B-lymphoid and myeloid lineage markers but are negative for MLL translocation and t(9;22)(q34;q11.2) translocation.


Mixed phenotype acute leukemia T/myeloid

A rare mixed phenotype acute leukemia in which the blasts express T-lymphoid and myeloid lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.


NK-lymphoblastic leukemia/lymphoma

A precursor lymphoid neoplasm that expresses CD56 and immature T-cell markers, lacks B-lymphoid and myeloid markers, and has immunoglobulin and T-cell receptor genes in the germline configuration.


Nasopharyngeal squamous cell carcinoma stage I

Stage I includes: T1, N0, M0. T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Nasopharyngeal lymphoepithelioma stage I


Nasopharyngeal squamous cell carcinoma stage II

Stage II includes: (T1, N1, M0); (T2, N0, M0); (T2, N1, M0).  T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Nasopharyngeal lymphoepithelioma stage II


Nasopharyngeal squamous cell carcinoma stage III

Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  T3: Nasopharyngeal cancer with tumor involving bony structures of skull base and/or paranasal sinuses.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)


Nasopharyngeal lymphoepithelioma stage III


Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7

Stage IV includes: IVA: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IVB (Any T, N3, M0); IVC (Any T, Any N, M1). T4: Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. N3: Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b.  M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)


Nasopharyngeal lymphoepithelioma stage IV


Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma

The reemergence of keratinizing squamous cell carcinoma of the nasopharynx after a period of remission.


The reemergence of undifferentiated carcinoma of the nasopharynx after a period of remission.


Hypopharyngeal squamous cell carcinoma stage I

Stage I includes: T1, N0, M0.  T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Hypopharyngeal squamous cell carcinoma stage II

Stage II includes: T2, N0, M0. T2: Tumor invades more than one subsite of the hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest diameter without fixation of hemilarynx.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Hypopharyngeal squamous cell carcinoma stage III

Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T3: Tumor measuring more than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus.  T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest dimension.  T2: Tumor invades more than one subsite of the hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest diameter without fixation of hemilarynx.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7

Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1).  T4a: Tumor with moderately advanced local disease.  Tumor invades the thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue.  Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.  T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest dimension.  T2: Tumor invades more than one subsite of the hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest diameter without fixation of hemilarynx.  T3: Tumor measuring more than 4 cm in greatest dimension or tumor with fixation of hemilarynx or extension to esophagus.  T4b: Tumor with very advanced local disease.  Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node more than 6 cm in greatest dimension.  M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


Hypopharyngeal squamous cell carcinoma recurrent

Reemergence of squamous cell carcinoma of the hypopharynx after a period of remission.


Stage I Laryngeal Squamous Cell Carcinoma AJCC v6 and v7

Stage I includes: T1, N0, M0.  T1: (Supraglottis) Tumor limited to one subsite of supraglottis with normal vocal cord mobility. (Glottis) Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility.  (Subglottis) Tumor limited to the subglottis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage I Laryngeal Verrucous Carcinoma AJCC v6 and v7


Stage II Laryngeal Squamous Cell Carcinoma AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: (Supraglottis) Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx.  (Glottis) Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility.  (Subglottis) Tumor extends to vocal cord(s) with normal or impaired mobility. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Stage II Laryngeal Verrucous Carcinoma AJCC v6 and v7


Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7

Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Supraglottis: Tumor limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility.  Subglottis: Tumor limited to the subglottis.  T2: Supraglottis: Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx.  Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility.  Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. T3: Supraglottis: Tumor limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, pre-epiglottic tissues, paraglottic space, and/or inner cortex of thyroid cartilage.  Glottis: Tumor limited to the larynx with vocal cord fixation and/or invasion of paraglottic space, and/or inner cortex of the thyroid cartilage.  Subglottis: Tumor limited to larynx with vocal cord fixation.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3cm or less in greatest dimension.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage III Laryngeal Verrucous Carcinoma AJCC v6 and v7


Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7

Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1).  T4a: Supraglottis: Moderately advanced local disease.  Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus).  Glottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus).  Subglottis: Moderately advanced local disease.  Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus).  T4b: Supraglottis, Glottis, and Subglottis: Very advanced local disease.  Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)


Laryngeal squamous cell carcinoma recurrent

The reemergence of squamous cell carcinoma of the larynx after a period of remission.


Laryngeal verrucous carcinoma recurrent

The reemergence of verrucous carcinoma of the larynx after a period of remission.


Adult T-cell lymphoma/leukemia stage I

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


Adult T-cell lymphoma/leukemia stage II

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Adult T-cell lymphoma/leukemia stage III

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


Adult T-cell lymphoma/leukemia stage IV

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Adult T-cell lymphoma/leukemia recurrent

The reemergence of adult T-cell leukemia/lymphoma after a period of remission


Treatment related acute myeloid leukaemia

An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation.  (WHO, 2001)


de novo Myelodysplastic Syndrome

A primary myelodysplastic syndrome not associated with prior radiation or chemotherapy treatment.


Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter

The reemergence of renal pelvis and ureter urothelial carcinoma after a period of remission.


Adult Anaplastic Astrocytoma

An astrocytoma occurring in adults that is characterized by the presence of high mitotic activity, cytologic atypia, and architectural distortion.


Stage I Uterine Sarcoma AJCC v7

Stage I includes: T1, N0, M0.  T1: Tumor limited to the uterus.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)


Stage II Uterine Sarcoma AJCC v7

Stage II includes: T2, N0, M0.  T2: Tumor extends beyond the uterus, within the pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)


Refractory Thrombocytopenia

A myelodysplastic syndrome characterized by the presence of at least 10% dysplastic megakaryocytes, found within at least 30 megakaryocytes examined in the bone marrow.


Stage III Uterine Sarcoma AJCC v7

Stage III includes: IIIA (T3a, N0, M0); IIIB (T3b, N0, M0); IIIC (T1-T3, N1, M0).  T1: Tumor limited to the uterus. T2: Tumor extends beyond the uterus, within the pelvis.  T3: Tumor infiltrates abdominal tissues.  T3a: Tumor infiltrates abdominal tissues, one side. T3b: Tumor infiltrates abdominal tissues, more than one side.  N0: No regional lymph node metastasis. N1: Regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)


Recurrent Uterine Corpus Sarcoma

The reemergence of uterine corpus sarcoma after a period of remission.


Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

A myelodysplastic/myeloproliferative neoplasm characterized by marked thrombocytosis, anemia, erythroid lineage dysplasia, presence or absence of multilineage dysplasia, 15% or more ring sideroblasts, blasts less than 5% in bone marrow and less than 1% in peripheral blood, absence of BCR/ABL fusion, absence of SF3B1 mutation, absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and no history of other myelodysplastic/myeloproliferative neoplasms or myeloproliferative neoplasms and myelodysplastic syndromes.


Adult Anaplastic (Malignant) Meningioma

An anaplastic (malignant) meningioma occurring in adults.


Localized Unresectable Neuroblastoma

Neuroblastoma that is confined to a specific site and is not amenable to surgical removal.


Long-Term Effects Secondary to Cancer Therapy in Children


Immunoblastic lymphoma associated with AIDS

A morphologic variant of diffuse large B-cell lymphoma occurring in HIV-positive patients.


Burkitt lymphoma associated with AIDS

A Burkitt lymphoma occurring in HIV-positive patients.


Adult Pineocytoma

A pineocytoma occurring in adults.


AIDS-Related Diffuse Mixed Cell Lymphoma

A non-Hodgkin lymphoma occurring in HIV-positive patients.  It is composed of a mixture of lymphocytes of various sizes.


AIDS-Related Diffuse Small Cleaved Cell Lymphoma

A non-Hodgkin lymphoma occurring in HIV-positive patients.  It is composed of small cleaved lymphocytes.


Tissue Congestion

A finding indicating the presence of increased blood volume in the vascular lumen.


AIDS-Related Lymphoblastic Lymphoma

A lymphoblastic lymphoma occurring in HIV-positive patients.


Adult Acute Myeloid Leukemia with Minimal Differentiation

An acute myeloid leukemia with minimal differentiation occurring in adults.


Childhood Acute Myeloid Leukemia with Minimal Differentiation

An acute myeloid leukemia with minimal differentiation occurring in children.


Stage I Childhood Large Cell Lymphoma

Stage I: Involvement of a single lymph node region (I) or localized involvement of a single extralymphatic organ or site (IE). (from PDQ)


Stage II Childhood Large Cell Lymphoma

Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ)


Stage III Childhood Large Cell Lymphoma

Stage III: Involvement of lymph node regions on both sides of the diaphragm (III) that may also be accompanied by localized involvement of an extralymphatic organ or site (IIIE), by involvement of the spleen (IIIS), or both (IIIS+E). (from PDQ)


Stage IV Childhood Large Cell Lymphoma

Stage IV: Disseminated (multifocal) involvement of one or more extralymphatic sites with or without associated lymph node involvement or isolated extralymphatic organ involvement with distant (nonregional) nodal involvement. (from PDQ)


Recurrent Childhood Large Cell Lymphoma

The reemergence of childhood large cell lymphoma after a period of remission.


Childhood Large Cell Lymphoma

A large cell lymphoma occurring in childhood.


Lymphoma stage III

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


Lymphoma stage IV

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Low Grade Squamous Intraepithelial Neoplasia

A precancerous neoplastic process characterized by the presence of mild dysplastic cytological changes which are usually present in the lower part of the squamous epithelium.  Representative examples include the low grade esophageal squamous intraepithelial neoplasia, low grade cervical squamous intraepithelial neoplasia, low grade vaginal intraepithelial neoplasia, and low grade vulvar intraepithelial neoplasia.


High-Grade Squamous Intraepithelial Lesions

A precancerous neoplastic process characterized by the presence of moderate or severe dysplastic cytological changes which extend to the upper part of the squamous epithelium.  Maturation at the surface of the squamous epithelium may or may not be present.  Representative examples include the high grade esophageal squamous intraepithelial neoplasia, high grade cervical squamous intraepithelial neoplasia, high grade vaginal intraepithelial neoplasia, and high grade vulvar intraepithelial neoplasia.


Recurrent Childhood Cerebellar Astrocytoma

Regrowth of benign and malignant childhood cerebellar astrocytomas that have previously been subjected to surgical resection and less frequently other forms of therapy such as radiation or chemotherapy.  Recurrence of benign tumors (e.g., (pilocytic astrocytoma) may respond to a second surgical procedure.


Carcinoma of base of tongue

A carcinoma that arises from the base of the tongue.  Representative examples include squamous cell carcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.


Stage 0 Cutaneous Melanoma AJCC v6 and v7

Stage 0 includes: Tis, N0, M0.  Tis: Melanoma in situ.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)


Atypical Ductal Breast Hyperplasia

A neoplastic process that arises from the terminal ductal lobular unit of the breast parenchyma.  It is usually solitary and confined to a single lobular unit.  It is characterized by the presence of a monomorphic epithelial proliferation in a cribriform, micropapillary, or solid growth pattern.  Focal architectural features of low grade ductal carcinoma in situ are present.  There is an increased risk for development of invasive breast carcinoma.


Bile Acid Synthesis Defect

A congenital or acquired defect in the bile acid biosynthesis, resulting in progressive liver disease.


Liver Disease Associated with Cystic Fibrosis

A spectrum of liver disorders that develop in patients with cystic fibrosis. It includes asymptomatic elevation of the liver function tests, steatosis, cholecystitis with cholelithiasis, sclerosing cholangitis, biliary cirrhosis, and cholangiocarcinoma.


Complications of Diabetes Mellitus

Organ or tissue damage due to diabetes mellitus. It includes heart disease and stroke, renal disease and renal failure, retinopathy, neuropathies, and erectile dysfunction.


Childhood Kidney Disorder

A kidney disorder that appears during childhood.


Pediatric Obesity

A condition in which a child's body mass index (BMI) falls at or above the 95th percentile based on the normative values for the age and sex of the reference population.


Mantle cell lymphoma stage I

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma


Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma


Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma

Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ).


Ann Arbor Stage II Contiguous Mantle Cell Lymphoma


Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma


Stage II Contiguous Adult Diffuse Large Cell Lymphoma


Hereditary Angioedema Types I and II

Autosomal dominant inherited disorders characterized by abnormalities of C1 inhibitor. Patients present with swelling of the skin, subcutaneous tissues, and mucosa sites. In type I hereditary angioedema, the plasma levels of C1 inhibitor are decreased. In type II hereditary angioedema, the C1 inhibitor is dysfunctional and its plasma levels may be normal or elevated.


Ann Arbor Stage II Contiguous Adult Lymphoblastic Lymphoma

Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ)


Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma


Ann Arbor Stage II Non-Contiguous Adult Lymphoblastic Lymphoma


Stage III Indolent Adult Non-Hodgkin Lymphoma

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


Stage IV Indolent Adult Non-Hodgkin Lymphoma

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Recurrent Indolent Adult Non-Hodgkin Lymphoma

The reemergence of indolent non-Hodgkin lymphoma in adults after a period of remission.


Mantle cell lymphoma recurrent

The reemergence of a mantle cell lymphoma after a period of remission.


Recurrent Aggressive Adult Non-Hodgkin Lymphoma

The reemergence of an aggressive adult non-Hodgkin lymphoma after a period of remission.


Indolent Adult Non-Hodgkin Lymphoma

An indolent non-Hodgkin lymphoma occurring in adults.  Representative examples include small lymphocytic lymphoma, lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia, marginal zone B-cell lymphoma, and grade 1 and 2 follicular lymphoma.


myotonic syndrome

An inherited or acquired, localized or generalized disorder affecting the muscles. It may be associated with abnormalities in the chloride or sodium channels of the muscles. It is characterized by delayed muscle relaxation following stimulation or contraction. Representative examples include myotonia congenita and myotonic dystrophy.


Indolent Non-Hodgkin Lymphoma

A non-Hodgkin lymphoma with an indolent clinical course.


Invasive Malignant Neoplasm

Cancer that has spread beyond the layer of tissue in which it developed and is growing into surrounding, healthy tissues.


Measurable Disease

A finding indicating that a subject has one or more measurable pathological lesions.


Primary Neoplasm

A tumor at the original site of origin.


Stage I Hodgkin Lymphoma

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE) (rare in Hodgkin lymphoma).


Stage II Non-Hodgkin Lymphoma

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). The number of regions involved may be indicated by a subscript (e.g., II3).


Locally Advanced Malignant Neoplasm

A malignant neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes.


Metastatic malignant neoplasm to chest wall

A malignant neoplasm that has spread to the structures of the chest wall from another primary anatomic site.


Malignant Paraganglionic Neoplasm

A paraganglioma that metastasizes to regional or distant anatomic sites.  Extraadrenal paragangliomas have a higher tendency to metastasize, as compared to pheochromocytomas.  Common sites of metastasis include the lymph nodes, lungs, bones, and liver.


Ann Arbor Stage II Adult Contiguous Immunoblastic Lymphoma


Ann Arbor Stage II Adult Non-Contiguous Immunoblastic Lymphoma


Neoplasms, Unknown Primary

The spread of a malignant neoplasm from an unknown primary to another region remote from the primary site.


Stage IIB Adult Soft Tissue Sarcoma AJCC v7


Localized Malignant Neoplasm

A malignant neoplasm that is confined to a specific site without evidence of spread to other anatomic sites.


Infiltrating Cervical Carcinoma

A carcinoma that arises from the cervix and invades into the stromal tissue.


Recurrent Childhood Ependymoma

The reemergence of ependymoma in childhood after a period of remission.


Stage IB Soft Tissue Sarcoma AJCC v7

Stage IB includes: (T2a, N0, M0, G1, GX); (T2b, N0, M0, G1, GX).  T2a: Superficial tumor more than 5 cm in greatest dimension.  T2b: Deep tumor more than 5 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Grade 1.  GX: Grade cannot be assessed. (AJCC 7th ed.)


Stage IIB Soft Tissue Sarcoma AJCC v7

Stage IIB includes: (T2a, N0, M0, G2); (T2b, N0, M0, G2).  T2a: Superficial tumor more than 5 cm in greatest dimension.  T2b: Deep tumor more than 5 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G2: Grade 2.  (AJCC 7th ed.)


Stage IA Breast Cancer AJCC v7

Stage IA includes: T1, N0, M0.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Stage IB Breast Cancer AJCC v7

Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Stage III Soft Tissue Sarcoma AJCC v7

Stage III includes: (T2a, T2b, N0, M0, G3); (Any T, N1, M0, Any G).  T2a: Superficial tumor more than 5 cm in greatest dimension.  T2b: Deep tumor more than 5 cm in greatest dimension.  N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  G3: Grade 3.  There is no T2a for the pathologic group. (AJCC 7th ed.)


Stage IV Soft Tissue Sarcoma AJCC v7

Stage IV includes: Any T, Any N, M1, Any G.  M1: Distant metastasis. (AJCC 7th ed.)


Autosomal Recessive Disorder

An inherited disorder manifested only when two copies of a mutated gene are present.


Stage I Merkel Cell Carcinoma AJCC v7

Stage I includes: IA: (T1, pN0, M0) and IB: (T1, cN0, M0).  T1: Primary tumor equal or less than 2 cm in size.  pN0: No regional lymph node metastasis by pathologic examination.  cN0: No regional lymph node metastasis by clinical examination.  M0: No distant metastasis.  (AJCC 7th Ed.)


Stage II Merkel Cell Carcinoma AJCC v7

Stage II includes: IIA: (T2/T3, pN0, M0), IIB: (T2/T3, cN0, M0), and IIC: (T4, N0, M0).  T2: Primary tumor greater than 2 cm but not more than 5 cm in maximum dimension.  T3: Primary tumor over 5 cm in maximum dimension.  T4: Primary tumor invades bone, muscle, fascia, or cartilage.  pN0: No regional lymph node metastasis by pathologic examination.  cN0: No regional lymph node metastasis by clinical examination.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th Ed.)


Stage III Merkel Cell Carcinoma AJCC v7

Stage III includes: IIIA: (Any T, N1a, M0) and IIIB: (Any T, N1b/N2, M0).  N1a: Micrometastasis in regional lymph nodes.  N1b: Macrometastasis in regional lymph nodes.  N2: In transit metastasis.  M0: No distant metastasis.  (AJCC 7th Ed.)


Stage IV Merkel Cell Carcinoma AJCC v7

Stage IV includes: Any T, Any N, M1.  M1: Metastasis beyond regional lymph nodes. (AJCC 7th Ed.)


Ache

A dull persistent (usually moderately intense) pain.


Stage IIA Cutaneous Melanoma AJCC v6 and v7

Stage IIA includes: (T2b, N0, M0); (T3a, N0, M0).  T2b: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, with ulceration.  T3a: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, without ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)


Stage IIC Cutaneous Melanoma AJCC v6 and v7

Stage IIC includes: T4b, N0, M0.  T4b: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, with ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)


The reemergence of lymphoplasmacytic lymphoma after a period of remission.


Stage IIIA Cutaneous Melanoma AJCC v7

Stage IIIA includes: (T1-4a, N1a, M0); (T1-4a, N2a, M0).  T1-4a: Non-ulcerated cutaneous melanoma of any thickness.  N1a: Cutaneous melanoma with micrometastasis in one regional lymph node.  N2a: Cutaneous melanoma with micrometastases in 2-3 regional lymph nodes.  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)


Stage IIIB Cutaneous Melanoma AJCC v7

Stage IIIB includes: (T1-4b, N1a, M0); (T1-4b, N2a, M0); (T1-4a, N1b, M0); (T1-4a, N2b, M0); (T1-4a, N2c, M0).  T1-4b: Ulcerated cutaneous melanoma of any thickness.  T1-4a: Non-ulcerated cutaneous melanoma of any thickness.  N1a: Cutaneous melanoma with micrometastasis in one regional lymph node.  N2a: Cutaneous melanoma with micrometastases in 2-3 regional lymph nodes.  N1b: Cutaneous melanoma with macrometastasis in one regional lymph node.  N2b: Cutaneous melanoma with macrometastases in 2-3 regional lymph nodes.  N2c: Cutaneous melanoma with intralymphatic metastases (in transit or satellite metastases) without metastatic nodes.  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)


Stage IIIC Cutaneous Melanoma AJCC v7

Stage IIIC includes: (T1-4b, N1b, M0); (T1-4b, N2b, M0); (T1-4b, N2c, M0); (Any T, N3, M0).  T1-4b: Ulcerated cutaneous melanoma of any thickness.  N1b: Cutaneous melanoma with macrometastasis in one regional lymph node.  N2b: Cutaneous melanoma with macrometastases in 2-3 regional lymph nodes.  N2c: Cutaneous melanoma with intralymphatic metastases (in transit or satellite metastases) without metastatic nodes.  N3: Cutaneous melanoma with 4 or more metastatic nodes, or matted nodes, or in transit met(s)/satellite(s) with metastatic node(s).  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)


Testicular choriocarcinoma stage II

Stage II includes: Any pT/TX, N1-3, M0, SX.  pTX: Primary tumor cannot be assessed.  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. SX: Marker studies not available or not performed.  (AJCC 6th and 7th eds.)


Inflammatory carcinoma of breast recurrent

The reemergence of inflammatory carcinoma of the breast after a period of remission


Malignant hepatobiliary neoplasms

A malignant neoplasm that affects the liver parenchyma, bile ducts, and gallbladder.  Representative examples include hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.


Chronic myelomonocytic leukemia (in remission)

A finding of chronic myelomonocytic leukemia that is not growing and responds to treatment.


Colorectal cancer recurrent

The reemergence of colorectal carcinoma after a period of remission.


Stage IV Gastric Cancer with Metastasis

T4,N2,MO (from PDQ)


Esophageal adenocarcinoma recurrent

An esophageal adenocarcinoma which has reappeared after a period of remission or after presumed treatment.


Stage II Esophageal Adenocarcinoma AJCC v7

Stage II includes: IIA (T2, N0, M0, G3); IIB (T3, N0, M0, Any G); (T1-2, N1, M0, Any G).  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  M0: No distant metastasis. G3: Poorly differentiated.  (AJCC 7th ed.)


Stage IV Esophageal Adenocarcinoma AJCC v7

Stage IV includes: Any T, Any N, M1, Any G.  M1: Distant metastasis.  (AJCC 7th ed.)


Esophageal squamous cell carcinoma recurrent

An esophageal squamous cell carcinoma which has reappeared after a period of remission or after presumed treatment.


Small intestine carcinoma non-resectable

Carcinoma of the small intestine not amendable to resection.


Bile duct cancer resectable

Extrahepatic bile duct carcinoma that is amenable to surgical removal.


Hepatoblastoma recurrent

The reemergence of hepatoblastoma after a period of remission.


Recurrent Chronic Lymphoid Leukemia

The reemergence of chronic lymphocytic leukemia after a period of remission.


Chronic lymphocytic leukemia stage 4

Risk: High; Findings: Lymphocytosis and platelets less than 100,000/microliter; Survival (months): 30. (from AJCC 8th Ed.)


Hodgkin's disease lymphocyte depletion type recurrent

The reemergence of lymphocyte-depleted classic Hodgkin lymphoma after a period of remission.


Hodgkin's disease lymphocyte depletion type refractory

Lymphocyte-depleted classic Hodgkin lymphoma that is resistant to treatment.


Hodgkin's disease lymphocyte depletion type stage IV

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Lymphoplasmacytic lymphoma resistant to treatment.


Adult T-cell lymphoma/leukemia refractory

Adult T-cell leukemia/lymphoma that is resistant to treatment.


Anaplastic large cell lymphoma T- and null-cell types refractory

Anaplastic large cell lymphoma resistant to treatment.


Stage II Anaplastic Large Cell Lymphoma

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Stage III Anaplastic Large Cell Lymphoma

Ann Arbor Classification. Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


T-cell lymphoma recurrent

The reemergence of T-cell non-Hodgkin lymphoma after a period of remission.


T-cell lymphoma refractory

T-cell non-Hodgkin lymphoma that is resistant to treatment.


T-cell lymphoma stage III

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


Angiocentric lymphoma refractory

Nasal type extranodal NK/T-cell lymphoma that does not respond to treatment.


Angioimmunoblastic T-cell lymphoma refractory

Follicular helper T-cell lymphoma, angioimmunoblastic-type that is resistant to treatment.


Angioimmunoblastic T-cell lymphoma recurrent

The reemergence of follicular helper T-cell lymphoma, angioimmunoblastic-type after a period of remission


Angioimmunoblastic T-cell lymphoma stage II


Angioimmunoblastic T-cell lymphoma stage III


Angioimmunoblastic T-cell lymphoma stage IV


Intestinal T-cell lymphoma recurrent

The reemergence of enteropathy-associated T-cell lymphoma after a period of remission.


Intestinal T-cell lymphoma refractory

Enteropathy-associated T-cell lymphoma that is resistant to treatment.


Mycosis fungoides recurrent

The reemergence of mycosis fungoides after a period of remission.


Mycosis fungoides refractory

Mycosis fungoides resistant to treatment.


Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

The reemergence of mature T-cell and NK-cell non-Hodgkin lymphoma after a period of remission.


Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Mature T-cell and NK-cell non-Hodgkin lymphoma that is resistant to treatment.


Precursor T-lymphoblastic lymphoma/leukemia recurrent

The reemergence of T-lymphoblastic leukemia/lymphoma after a period of remission.


Stage IIIA Vulvar Cancer AJCC v7

Stage IIIA includes: (T1/T2, N1a/N1b, M0); T1: Invasive vulvar cancer confined to the vulva or perineum.  T2: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).  N1a: Vulvar cancer with one or two lymph node metastasis each measuring 5 mm or less.  N1b: Vulvar cancer with one lymph node metastasis measuring 5 mm or greater.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIB Vulvar Cancer AJCC v7

Stage IIIB includes: (T1/T2, N2a/N2b, M0).  T1: Invasive vulvar cancer confined to the vulva or perineum.  T2: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).  N2a: Vulvar cancer with three or more lymph node metastases each measuring 5 mm or less.  N2b: Vulvar cancer with two or more lymph node metastases measuring 5 mm or greater.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIC Vulvar Cancer AJCC v7

Stage IIIC includes: (T1/T2, N2c, M0).  T1: Invasive vulvar cancer confined to the vulva or perineum.  T2: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).  N2c: Vulvar cancer with lymph node metastasis with extracapsular spread.  M0: No distant metastasis.  (AJCC 7th ed.)


Non-Hodgkin's lymphoma refractory

A non-Hodgkin lymphoma which does not respond to treatment.


Non-Hodgkin's lymphoma transformed recurrent

The reemergence of non-Hodgkin lymphoma transformed after a period of remission.


Peritoneal mesothelioma malignant recurrent

The reemergence of malignant peritoneal mesothelioma after a period of remission.


HPV positive oropharyngeal squamous cell carcinoma

A squamous cell carcinoma that arises from the oropharynx and is associated with human papillomavirus type 16 infection.


Pleural mesothelioma malignant advanced

Malignant mesothelioma that arises from the pleura and is classified as stage II, stage III, or stage IV.


Pleural mesothelioma malignant recurrent

The reemergence of pleural malignant mesothelioma after a period of remission.


Rhesus hemolytic disease of newborn

A disorder caused when there is a Rh-factor blood-type incompatibility between the mother and fetus, and the mother's immune system forms antibodies that attack the red blood cells of her unborn child. This disorder can only occur if the mother is Rh-negative and the fetus is Rh-positive.


Stage IA Uterine Sarcoma AJCC v7

Stage IA includes: T1a, N0, M0.  T1a: For leiomyosarcoma and endometrial stromal sarcoma: tumor 5 cm or less in greatest dimension.  For adenosarcoma: tumor limited to endometrium/endocervix.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IB Uterine Sarcoma AJCC v7

Stage IB includes: T1b, N0, M0.  T1b: For leiomyosarcoma and endometrial stromal sarcoma: tumor more than 5 cm in greatest dimension.  For adenosarcoma: tumor invades to less than half of the myometrium.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IC Uterine Sarcoma AJCC v7

Stage IC includes: T1c, N0, M0.  T1c: For adenosarcoma: tumor invades more than half of the myometrium.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  Stage IC does not apply for leiomyosarcoma and endometrial stromal sarcoma.  (AJCC 7th ed.)


Stage IIIA Uterine Sarcoma AJCC v7

Stage IIIA includes: T3a, N0, M0.  T3a: Tumor infiltrates abdominal tissues, one side. N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)


Stage IIIB Uterine Sarcoma AJCC v7

Stage IIIB includes: T3b, N0, M0. T3b: Tumor infiltrates abdominal tissues, more than one side.  N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)


Stage IIIC Uterine Sarcoma AJCC v7

Stage IIIC includes: T1-T3, N1, M0.  T1: Tumor limited to the uterus. T2: Tumor extends beyond the uterus, within the pelvis.  T3: Tumor infiltrates abdominal tissues.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)


Stage IVA Uterine Sarcoma AJCC v7

Stage IVA includes: T4, Any N, M0. T4: Tumor involves bladder or rectum.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)


Intraocular Pressure

The fluid pressure within the eye.


Stage IVB Uterine Sarcoma AJCC v7

Stage IVB includes: Any T, Any N, M1.  M1: Distal metastasis (excluding adnexa, pelvic and abdominal tissues).  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)


Visual Acuity

Sharpness of vision, the ability to discern fine detail.


Stage I Gestational Trophoblastic Tumor AJCC v7

Stage I includes: (T1, M0, Risk factors: unknown); IA (T1, M0, Risk factors: low risk); IB (T1, M0, Risk factors: high risk).  T1: Tumor confined to uterus.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage II Gestational Trophoblastic Tumor AJCC v7

Stage II includes: (T2, M0, Risk factors: unknown); IIA (T2, M0, Risk factors: low risk); IIB (T2, M0, Risk factors: high risk).  T2: Tumor extends to other genital structures (ovary, tube, vagina, broad ligaments) by metastasis or direct extension.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage III Gestational Trophoblastic Tumor AJCC v7

Stage III includes: (Any T, M1a, Risk factors: unknown); IIIA (Any T, M1a, Risk factors: low risk); IIIB (Any T, M1a, Risk factors: high risk).  M1a: Lung metastasis.  (AJCC 7th ed.)


Stage IA Pleural Malignant Mesothelioma AJCC v7

Stage IA includes: T1a, N0, M0.  T1a: Pleural mesothelioma with no involvement of the visceral pleura. N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IB Pleural Malignant Mesothelioma AJCC v7

Stage IB includes: T1b, N0, M0.  T1b: Pleural mesothelioma with a tumor also involving the visceral pleura N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage II Fallopian Tube Cancer

Stage II includes: (T2, N0, M0); IIA: (T2a, N0, M0); IIB (T2b, N0, M0); IIC (T2c, N0, M0).  T2: Tumor involves one or both fallopian tubes with pelvic extension.  T2a: Extension and/or metastasis to the uterus and/or ovaries.  T2b: Extension to other pelvic structures.  T2c: Pelvic extension with malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7

Stage III includes: T3, N0, M0. T3: Tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Ovarian germ cell choriocarcinoma stage I

Stage I includes: T1, N0, M0. T1: Tumor limited to ovaries (one or both). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Ovarian germ cell choriocarcinoma stage II


Ovarian germ cell choriocarcinoma stage III


Ovarian germ cell choriocarcinoma stage IV


Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7

Stage I includes: (T1, N0, M0). T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7


Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7


Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7


Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7


Large cell lung cancer recurrent

The reemergence of large cell lung carcinoma after a period of remission.


Stage III Mucosal Melanoma of the Head and Neck AJCC v7

Stage III includes: T3, N0, M0.  T3: Mucosal disease N0: No regional lymph node metastases.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7

Stage IVA includes: (T4a, N0, M0); (T3-T4a, N1, M0).  T4a: Moderately advanced disease.  Tumor involves deep soft tissue, cartilage, bone, or overlying skin.  T3: Mucosal disease.  N0: No regional lymph node metastases.  N1: Tumor with regional lymph node metastases.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7

Stage IVB includes: T4b, Any N, M0.  T4b: Very advanced disease.  Tumor involves brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7

Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


Stage III Differentiated Thyroid Gland Carcinoma AJCC v7

Stage III includes: (T3, N0, M0); (T1, N1a, M0); (T2, N1a, M0); (T3, N1a, M0). T3: Tumor greater than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  M0: No distant metastasis. (AJCC 7th ed.)


Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7

Stage IVA includes: (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0). T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII).  M0: No distant metastasis. (AJCC 7th ed.)


Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7

Stage IVB includes: T4b, Any N, M0. T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7


Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7

Stage IVA includes: (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0).  T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0: No distant metastasis.  (AJCC 7th ed.)


Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7

Stage IVB includes: T4b, Any N, M0.  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7

Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis.  (AJCC 7th ed.)


Stage IVA Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v7

Stage IVA includes: T4a, Any N, M0.  T4a: Intrathyroidal anaplastic carcinoma. M0: No distant metastasis.  (AJCC 7th ed.)


Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v7

Stage IVB includes: T4b, Any N, M0.  T4b: Anaplastic carcinoma with gross extrathyroid extension.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IVC Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v7


Large cell lung cancer stage IV

Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


Lung adenocarcinoma recurrent

The re-emergence of lung adenocarcinoma after a period of remission.


Adenocarcinoma of lung, stage I

Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Adenocarcinoma of lung, stage III

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Lung Squamous Cell Carcinoma AJCC v7


Stage III Pharynx Carcinoma

Stage III carcinoma of the pharynx according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.


Stage IV Pharynx Carcinoma

Stage IV carcinoma of the pharynx according to the American Joint Committee on Cancer, 6th, 7th, and 8th editions.


Stage IV Lung Cancer AJCC v6

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis present. (AJCC 6th ed.)


Stage IIA Gastric Cancer AJCC v7

Stage IIA includes: (T3, N0, M0); (T2, N1, M0); (T1, N2, M0). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades the muscularis propria. T3: Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures.  N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IIB Gastric Cancer AJCC v7

Stage IIB includes: (T4a, N0, M0); (T3, N1, M0); (T2, N2, M0); (T1, N3, M0).  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades the muscularis propria. T3: Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures.  T4a: Tumor invades serosa (visceral peritoneum).  N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IIIC Gastric Cancer AJCC v7

Stage IIIC includes: (T4b, N2, M0); (T4b, N3, M0); (T4a, N3, M0).  T4a: Tumor invades serosa (visceral peritoneum).  T4b: Tumor invades adjacent structures. N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis.  (AJCC 7th ed.)


Stage IB Esophageal Adenocarcinoma AJCC v7

Stage IB includes: (T1, N0, M0, G3); (T2, N0, M0, G1-2, GX).  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  G2: Moderately differentiated.  G3: Poorly differentiated.  GX: Grade cannot be assessed-stage grouping as G1. (AJCC 7th ed.)


Stage IIIA Esophageal Adenocarcinoma AJCC v7

Stage IIIA includes: (T1-2, N2, M0, Any G); (T3, N1, M0, Any G); (T4a, N0, M0, Any G). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T4a: Resectable tumor invading pleura, pericardium, or diaphragm. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIB Esophageal Adenocarcinoma AJCC v7

Stage IIIB includes: T3, N2, M0, Any G. T3: Tumor invades adventitia. N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIC Esophageal Adenocarcinoma AJCC v7

Stage IIIC includes: (T4a, N1-2, M0, Any G); (T4b, Any N, M0, Any G); (Any T, N3, M0, Any G).  T4a: Resectable tumor invading pleura, pericardium, or diaphragm. T4b: Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v7

Stage IIIB includes: T3, N2, M0, Any G, Tumor location: Any. T3: Tumor invades adventitia. N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Stage IIIC Esophageal Squamous Cell Carcinoma AJCC v7

Stage IIIC includes: (T4a, N1-2, M0, Any G, Tumor location: Any); (T4b, Any N, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any).  T4a: Resectable tumor invading pleura, pericardium, or diaphragm. T4b: Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc. N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Chondrosarcoma metastatic

A chondrosarcoma that has spread to a secondary anatomical site.


Stage IIIA Small Intestinal Cancer AJCC v7

Stage IIIA includes: Any T, N1, M0. N1: Metastasis in 1-3 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIB Small Intestinal Cancer AJCC v7

Stage IIIB includes: Any T, N2, M0. N2: Metastasis in four or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Secondary Central Nervous System Lymphoma

A non-Hodgkin or Hodgkin lymphoma that has spread to the central nervous system following the initial presentation in another nodal or extranodal site.


Stage IIIA Colorectal Cancer AJCC v7

Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  N1: Metastasis in 1-3 regional lymph nodes.  N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIB Colorectal Cancer AJCC v7

Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  T3: Tumor invades through the muscularis propria into pericolorectal tissues.  T4a: Tumor penetrates to the surface of the visceral peritoneum.  N1: Metastasis in 1-3 regional lymph nodes.  N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis.  N2a: Metastasis in 4-6 regional lymph nodes.  N2b: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIC Colorectal Cancer AJCC v7

Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0).  T3: Tumor invades through the muscularis propria into pericolorectal tissues.  T4a: Tumor penetrates to the surface of the visceral peritoneum.  T4b: Tumor directly invades or is adherent to other organs or structures. N1: Metastasis in 1-3 regional lymph nodes.  N2: Metastasis in four or more regional lymph nodes.  N2a: Metastasis in 4-6 regional lymph nodes.  N2b: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IVA Colorectal Cancer AJCC v7

Stage IVA includes: Any T, Any N, M1a.  M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node).  (AJCC 7th ed.)


Stage IVB Colorectal Cancer AJCC v7

Stage IVB includes: Any T, Any N, M1b.  M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)


Stage III Acral Lentiginous Melanoma AJCC v7

Stage III includes: Any T, N1-3, M0.  Stage III is divided into three pathologic subgroups: IIIA, IIIB, and IIIC.  There are no clinical subgroups for stage III.  N1: Cutaneous melanoma with metastasis in one regional lymph node.  N2: Cutaneous melanoma with metastases in 2-3 regional lymph nodes or in transit met(s)/satellite(s) without metastatic nodes.  N3: Cutaneous melanoma with 4 or more metastatic nodes, or matted nodes, or in transit met(s)/satellite(s) with metastatic node(s).  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)


Stage IV Acral Lentiginous Melanoma AJCC v6 and v7

Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis. (from AJCC 6th and 7th Eds.)


Malignant fibrous histiocytoma recurrent

Reemergence of undifferentiated pleomorphic sarcoma after a period of remission.


Alveolar soft part sarcoma metastatic

An alveolar soft part sarcoma which has spread to another anatomic site.


Alveolar soft part sarcoma recurrent

The reemergence of alveolar soft part sarcoma after a period of remission.


Epithelioid sarcoma metastatic

An epithelioid sarcoma which has spread to another anatomic site.


Extra-osseous Ewing's sarcoma non-metastatic

Ewing sarcoma that arises from the soft tissue and is confined to a specific site without evidence of spread to other anatomic sites.


Stage IIIC Hepatocellular Carcinoma AJCC v7

Stage IIIC includes: T4, N0, M0.  T4: Tumors(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)


Stage III Intrahepatic Cholangiocarcinoma AJCC v7

Stage III includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum or involving the local extra hepatic structures by direct invasion. N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7

Stage IVA includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor with periductal invasion. N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7

Stage IVB includes: Any T, Any N, M1.  M1: Distant metastasis. (from AJCC 7th Ed.)


Stage IIIA Gallbladder Cancer AJCC v7

Stage IIIA includes: T3, N0, M0. T3: Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IIIB Gallbladder Cancer AJCC v7

Stage IIIB includes: T1-3, N1, M0. T1: Tumor invades lamina propria or muscular layer.  T2: Tumor invades perimuscular connective tissue; no extension beyond serosa or into liver. T3: Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts.  N1: Metastases to nodes along the cystic duct, common bile duct, hepatic artery, and/or portal vein. M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IV Distal Bile Duct Cancer AJCC v7

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis.  (from AJCC 7th Ed.)


Stage IA Pancreatic Cancer AJCC v6 and v7

Stage IA includes: T1, N0, M0. T1: Tumor limited to the pancreas, 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IB Pancreatic Cancer AJCC v6 and v7

Stage IB includes: T2, N0, M0. T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IIA Pancreatic Cancer AJCC v6 and v7

Stage IIA includes: T3, N0, M0.  T3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IIB Pancreatic Cancer AJCC v6 and v7

Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Tumor limited to the pancreas, 2 cm or less in greatest dimension.  T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension. T3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IIA Prostate Cancer AJCC v7

Stage IIA includes: (T1a-c, N0, M0, PSA less than 20, Gleason 7); (T1a-c, N0, M0, PSA equal or more than 10 and less than 20, Gleason equal or less than 6); (T2a, N0, M0, PSA less than 20, Gleason equal or less than 7); (T2b, N0, M0, PSA less than 20, Gleason equal or less than 7); (T2b, N0, M0, PSA X, Gleason X). T1a: Tumor incidental histologic finding in 5% or less of tissue resected.  T1b: Tumor incidental histologic finding in more than 5% of tissue resected.  T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA).  T2a: Tumor involves one-half of one lobe or less.  T2b: Tumor involves more than one-half of one lobe, but not both lobes.  cN0: No regional lymph node metastasis.  pN0: No positive regional nodes.  M0: No distant metastasis.  Gleason 7: Moderately differentiated (moderate anaplasia).  Gleason Equal or Less than 6: Well differentiated (slight anaplasia).  (AJCC 7th ed.)


Stage IIB Prostate Cancer AJCC v7

Stage IIB includes: (T2c, N0, M0, Any PSA, Any Gleason); (T1-2, N0, M0, PSA equal or more than 20, Any Gleason); (T1-2, N0, M0, Any PSA, Gleason equal or more than 8).  T2c: Tumor involves both lobes.  T1a: Tumor incidental histologic finding in 5% or less of tissue resected.  T1b: Tumor incidental histologic finding in more than 5% of tissue resected.  T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA).  T2a: Tumor involves one-half of one lobe or less.  T2b: Tumor involves more than one-half of one lobe, but not both lobes.  cN0: No regional lymph node metastasis.  pN0: No positive regional nodes.  M0: No distant metastasis.  Gleason equal or more than 8: Poorly differentiated/undifferentiated (marked anaplasia).  (AJCC 7th ed.)


Fibrosarcoma metastatic

Fibrosarcoma that has spread from its original site of growth to another anatomic site.


Metastatic leiomyosarcoma

A leiomyosarcoma that has spread to other anatomic sites.


Stage IIA Uveal Melanoma AJCC v7

Stage IIA includes: (T1b-d, N0, M0); (T2a, N0, M0). T1b: Iris: Tumor limited to the iris more than 3 clock hours in size.  Ciliary body and choroid: Tumor size category 1 with ciliary body involvement.  T1c: Iris: Tumor limited to the iris with secondary glaucoma.  Ciliary body and choroid: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter.  T1d: Ciliary body and choroid: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. T2a: Iris: Tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma.  Ciliary body and choroid: Tumor size category 2 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIB Uveal Melanoma AJCC v7

Stage IIB includes: (T2b, N0, M0); (T3a, N0, M0).  T2b: Ciliary body and choroid: Tumor size category 2 with ciliary body involvement.  T3a: Iris: Tumor confluent with or extending into the ciliary body, choroid, or both, with sclera extension and secondary glaucoma. Ciliary body and choroid: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIA Uveal Melanoma AJCC v7

Stage IIIA includes: (T2c-d, N0, M0); (T3b-c, N0, M0); (T4a, N0, M0).  T2c: Ciliary body and choroid: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter. T2d: Ciliary body and choroid: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. T3b: Ciliary body and choroid: Tumor size category 3 with ciliary body involvement. T3c: Ciliary body and choroid: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter. T4a: Iris: Tumor with extrascleral extension less than or equal to 5 mm in diameter.  Ciliary body and choroid: Tumor size category 4 without ciliary body involvement and extraocular extension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)